Phase 3 N=153 Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy
Intrauterine Fetal Demise
Primary: Successful Expulsion of Fetus and Placenta Within 48 Hours — 60; 47 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=251 Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption
Placenta, Retained · Postpartum Hemorrhage
Primary: Placental Retention Rate — 26; 8; 24 participants — p=0.05
Phase 3 N=4 Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss
Spontaneous Abortion in First Trimester
Primary: Patient Enrollment — 2; 2 Participants
N/A N=135 Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion
Medical; Abortion, Fetus
Primary: Cervicovaginal Fetal Fibronectin Level — 39.4 nanogram per milliliter
Phase 4 N=30 Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial
Abortion, Second Trimester · PPROM · Rupture, Spontaneous
Primary: Delivery Within 12 Hours — 5; 5 Participants
N/A N=181 A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions
First Trimester Abortion
Primary: Nausea Scale — 8; 9; 6; 6 Participants
N/A N=500 Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion
Induced Abortion
Primary: Accurate Confirmation of Completed Abortion — 182; 164 participants — p=.13
N/A N=50 The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage
Circulating Cell Free Fetal DNA · Intrauterine Fetal Demise · Miscarriage
Primary: The Presence or Absence of Cell Free Fetal DNA in Maternal Blood in the Setting of a Failed Pregnancy. — 50 percentage of participants
N/A N=20 Cervix Monitor for Elasticity and Length Measurements
Preterm Birth
Primary: Cervix Elasticity — 54; 19.7 kPa
N/A N=50 Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks
Abortion
Primary: Time for Completion of Procedure — 8.0; 9.87 Minutes — p=0.05
N/A N=120 Insertion of an Intrauterine Device (IUD) After Medical Abortion
Intrauterine Device Expulsion · Medical Abortion · Induced Abortion
Primary: Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion. — 4 percentage of participants
Phase 4 N=100 Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation
Induced Abortion
Primary: Initial Cervical Dilation — 11.7; 10.9 mm
N/A N=51 The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location
Follow-up After Uterine Evacuation
Primary: Number of Women in Each Group Who Require a Return Visit to the Clinic for a Serum hCG Measurement, Ultrasound or Clinical Examination at One Week to Confirm Complete…
N/A N=36 Rebif® Pregnancy Registry
Multiple Sclerosis
Primary: Spontaneous Abortion — 2; 0 Participants
Phase 2 N=3 Ulipristal Acetate for Use in Early Pregnancy Loss
Missed Abortion · Anembryonic Pregnancy · Non-Viable Pregnancy
Primary: Percentage of Participants Recruited to Study Protocol — 37.5 percentage of participants
N/A N=634 Transabdominal and Transvaginal Sonography in Medical Abortion
Abortion Early
Primary: Percentage of Subjects in Each Ultrasound Group With Additional Testing — 63; 14 Participants
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
N/A N=300 Cervical Preparation Before Dilation and Evacuation
Abortion, Induced
Primary: Operative Time — 6.27; 6.28; 5.53 minutes
N/A N=1,228 The Effects of Aspirin in Gestation and Reproduction
Birth · Spontaneous Abortion
Primary: Live Birth — 309; 286 livebirths — p=0.0984
N/A N=60 Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion
Abortion, Induced
Primary: Patient Discomfort With Digoxin Injection (Pain Score) — 2.21; 1.88 Units on a scale — p=0.36
Phase 4 N=70 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E
Abortion, Second Trimester
Primary: Procedure Time — 9.5; 9.9 minutes
Phase 3 N=50 Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks
Cervical Preparation
Primary: Length of Procedure — 14; 13.5 minutes
Phase 3 N=300 Comparative Effectiveness of Pregnancy Failure Management Regimens
Spontaneous Abortion
Primary: Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment. — 100; 124…
Phase 4 N=250 Pain Control In First Trimester Medical Abortion: A Randomized Trial
Pain
Primary: 11-point Visual Analog Scale for Pain — 7.1; 7.3 units on a scale
Phase 2 N=69 Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 16; 30 Participants
Phase 4 N=326 Medication Abortion Via Pharmacy Dispensing
Pregnancy Related · Abortion Early
Primary: Number of Pharmacists Who Objected to Participate in Dispensing Mifeprex — 4 Participants
N/A N=80 Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services
Legally Induced Abortion Without Mention of Complication
Primary: Procedure Time — 13; 12; 18.5 minutes
N/A N=246 Contraceptive Counseling Following an Abortion
Post Abortion Care
Primary: Contraceptive Acceptability and Use of Contraceptives During the 6-month Follow-up — 121; 86 participants
N/A N=50 Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks
Abortion, Induced
Primary: Procedure Time — 10.9; 11.8 minutes
Phase 4 N=88 'Levonorgestrel IUD Insertion After D&E Procedure
Contraceptive Usage
Primary: The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment. — 85.2; 62.9 percentage of participants — p=0.05